Clinica Chimica Acta:克罗恩病患者肠粘膜上长链非编码RNA及其靶基因的表达变化

2019-09-13 gladiator MedSci原创

克罗恩病是一种慢性消化道特发性炎症性疾病。该疾病在全球范围内不断增加,并已成为一个全球性的健康问题。然而,目前关于<span lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:14.0pt;font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;; mso-fareast-font-

克罗恩病是一种慢性消化道特发性炎症性疾病。该疾病在全球范围内不断增加,并已成为一个全球性的健康问题。然而,目前关于CD发病的关键病理机制尚未明确,治疗多为抗症状治疗,疗效非常有限。本研究就lncRNA是否参与CD的发病机制,以及lncRNACD过程中如何调控靶基因分析。

研究纳入于20175月至20185月在东南大学中大医院确诊的患者。收集病理和正常肠粘膜,提取总RNA,利用lncRNAmRNA基因芯片分析lncRNAmRNA的表达情况。鉴定并验证了具有显着变化(≥10倍和P <0.05)的lncRNAmRNA。通过CNC分析揭示具有差异表达的lncRNA的共表达的mRNA。利用miRbaseTargetscanNCBI数据库,通过Ce (cis/tans)机制分析,确定潜在的调控因素。最后,预测lncRNA-miRNA/TF-mRNA表达网络。

结果显示,8lncRNA在回肠末端的病理黏膜和正常黏膜中均有差异表达。差异表达的lncRNACNC分析显示50个共表达的mRNA为正调节或负调节。通过对mRNAs KEGG通路的分析,发现其中大部分参与了细胞信号通路。细胞质中的6lncRNA参与了Ce机制,其余两个核中的lncRNA参与了顺式/反式调控机制。最后,通过CNCKEGG富集分析和Ce(反式/顺式)分析获得了lncRNAs-miRNATFs-mRNA的三元关系。

lncRNACD黏膜中的差异表达表明lncRNA 参与了免疫反应。这些lncRNAs可能通过lncRNAs-miRNA/TFs-mRNAs的遗传网络参与肠道粘膜功能的调控。

原始出处:

Na LiRuihua ShiExpression alteration of long non-coding RNAs and their target genes in the intestinal mucosa of patients with Crohns disease

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849694, encodeId=ecbb184969445, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Sep 15 18:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691043, encodeId=6281169104387, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Dec 09 14:41:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743505, encodeId=8bf31e4350544, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Apr 03 13:41:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313180, encodeId=dcd31313180f5, content=<a href='/topic/show?id=64dd9996046' target=_blank style='color:#2F92EE;'>#靶基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99960, encryptionId=64dd9996046, topicName=靶基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485840, encodeId=bd9614858407c, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584753, encodeId=ba901584e53b8, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=)]
    2019-09-15 windight
  2. [GetPortalCommentsPageByObjectIdResponse(id=1849694, encodeId=ecbb184969445, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Sep 15 18:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691043, encodeId=6281169104387, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Dec 09 14:41:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743505, encodeId=8bf31e4350544, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Apr 03 13:41:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313180, encodeId=dcd31313180f5, content=<a href='/topic/show?id=64dd9996046' target=_blank style='color:#2F92EE;'>#靶基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99960, encryptionId=64dd9996046, topicName=靶基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485840, encodeId=bd9614858407c, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584753, encodeId=ba901584e53b8, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1849694, encodeId=ecbb184969445, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Sep 15 18:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691043, encodeId=6281169104387, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Dec 09 14:41:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743505, encodeId=8bf31e4350544, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Apr 03 13:41:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313180, encodeId=dcd31313180f5, content=<a href='/topic/show?id=64dd9996046' target=_blank style='color:#2F92EE;'>#靶基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99960, encryptionId=64dd9996046, topicName=靶基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485840, encodeId=bd9614858407c, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584753, encodeId=ba901584e53b8, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=)]
    2020-04-03 d830384
  4. [GetPortalCommentsPageByObjectIdResponse(id=1849694, encodeId=ecbb184969445, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Sep 15 18:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691043, encodeId=6281169104387, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Dec 09 14:41:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743505, encodeId=8bf31e4350544, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Apr 03 13:41:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313180, encodeId=dcd31313180f5, content=<a href='/topic/show?id=64dd9996046' target=_blank style='color:#2F92EE;'>#靶基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99960, encryptionId=64dd9996046, topicName=靶基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485840, encodeId=bd9614858407c, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584753, encodeId=ba901584e53b8, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=)]
    2019-09-15 chengjn
  5. [GetPortalCommentsPageByObjectIdResponse(id=1849694, encodeId=ecbb184969445, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Sep 15 18:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691043, encodeId=6281169104387, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Dec 09 14:41:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743505, encodeId=8bf31e4350544, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Apr 03 13:41:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313180, encodeId=dcd31313180f5, content=<a href='/topic/show?id=64dd9996046' target=_blank style='color:#2F92EE;'>#靶基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99960, encryptionId=64dd9996046, topicName=靶基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485840, encodeId=bd9614858407c, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584753, encodeId=ba901584e53b8, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1849694, encodeId=ecbb184969445, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Sep 15 18:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691043, encodeId=6281169104387, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Dec 09 14:41:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743505, encodeId=8bf31e4350544, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Apr 03 13:41:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313180, encodeId=dcd31313180f5, content=<a href='/topic/show?id=64dd9996046' target=_blank style='color:#2F92EE;'>#靶基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99960, encryptionId=64dd9996046, topicName=靶基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485840, encodeId=bd9614858407c, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584753, encodeId=ba901584e53b8, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sun Sep 15 12:41:00 CST 2019, time=2019-09-15, status=1, ipAttribution=)]

相关资讯

GUT:anti-TNF并没有降低炎症性肠病患者的住院率和肠切除率

背景为了更好地了解生物疗法对克罗恩病(CD)和溃疡性结肠炎(UC)患者的现实影响,研究人员评估了英夫利昔单抗对患者住院率,手术率及支付药物成本产生的作用。方法研究人员使用了1995年至2012年间居住在加拿大安大略省的成人UC和CD患者的健康管理数据,进行分段回归分析的间歇时间序列设计来评估英夫利昔单抗对10年以上CD患者及5年以上UC患者住院率、手术率及公共药物支出的影响。结果与预期相比,英夫利

神一样的“克罗恩病”和“肠结核”,长得有点像!

典型的克罗恩病(CD),诊断和鉴别诊断比较容易。但是,大多数克罗恩病并不典型,需要与其他肠道溃疡性疾病进行鉴别诊断。常见的肠道溃疡性疾病包括克罗恩病、溃疡性结肠炎(UC)、肠结核(IT)、肠道淋巴瘤、肠型白塞病、溃疡型肠癌。其中,克罗恩病与肠结核、肠道淋巴瘤在临床表现、内镜所见非常相似,不易鉴别,有时需要进行诊断性治疗以及较长时间的评估来进行鉴别诊断!

2019 CAG临床实践指南:儿童腔内克罗恩病的医学治疗

2019年,加拿大胃肠病学协会(CAG)发布了儿童腔内克罗恩病的医学治疗指南,主要目的是为儿童腔内克罗恩病的管理提供指导,指南全文共包括25条声明建议,涉及各种治疗选择。

Gastroenterology:小肠克罗恩病伴狭窄的组织病理学评分系统

研究认为,目前缺乏有效的组织病理学评分系统来评估克罗恩病相关纤维肌肉狭窄,组织病理学指标的开发和验证是将来的研究重点

2019 CAG临床实践指南:腔内克罗恩病的管理

2019年,加拿大胃肠病学协会(CAG)发布了腔内克罗恩病的管理指南,克罗恩病是一种终身性疾病,尽管已有新的治疗方法和治疗模式,但仍不能治愈。本文主要针对中-重度活动性腔内克罗恩病的门诊治疗提供指导建议。

Takeda的Entyvio维多利珠单抗皮下制剂治疗克罗恩病,临床试验达到终点

Takeda的Entyvio药物皮下制剂在治疗克罗恩病方面有了新的临床数据,扩大了该药物在溃疡性结肠炎之外的可能性。